| # | Title | Journal | Year | Citations |
|---|
| 1 | SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates | Npj Vaccines | 2021 | 507 |
| 2 | Turning the corner on therapeutic cancer vaccines | Npj Vaccines | 2019 | 490 |
| 3 | The promise of mRNA vaccines: a biotech and industrial perspective | Npj Vaccines | 2020 | 303 |
| 4 | The how’s and what’s of vaccine reactogenicity | Npj Vaccines | 2019 | 302 |
| 5 | Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses | Npj Vaccines | 2020 | 286 |
| 6 | Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want | Npj Vaccines | 2018 | 252 |
| 7 | Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action | Npj Vaccines | 2021 | 241 |
| 8 | Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 | Npj Vaccines | 2021 | 198 |
| 9 | The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines | Npj Vaccines | 2020 | 195 |
| 10 | Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines | Npj Vaccines | 2017 | 181 |
| 11 | Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic | Npj Vaccines | 2021 | 175 |
| 12 | Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity | Npj Vaccines | 2017 | 171 |
| 13 | Antibody therapies for the prevention and treatment of viral infections | Npj Vaccines | 2017 | 156 |
| 14 | Malaria vaccines since 2000: progress, priorities, products | Npj Vaccines | 2020 | 154 |
| 15 | Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases | Npj Vaccines | 2021 | 154 |
| 16 | The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial | Npj Vaccines | 2018 | 135 |
| 17 | Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females | Npj Vaccines | 2019 | 124 |
| 18 | Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge | Npj Vaccines | 2021 | 123 |
| 19 | Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 | Npj Vaccines | 2020 | 121 |
| 20 | In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine | Npj Vaccines | 2016 | 118 |
| 21 | mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents | Npj Vaccines | 2021 | 118 |
| 22 | Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations | Npj Vaccines | 2018 | 114 |
| 23 | A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies | Npj Vaccines | 2017 | 113 |
| 24 | Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection | Npj Vaccines | 2020 | 109 |
| 25 | Protein-based antigen presentation platforms for nanoparticle vaccines | Npj Vaccines | 2021 | 105 |
| 26 | Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 | Npj Vaccines | 2021 | 102 |
| 27 | The antibody response induced FMDV vaccines in sheep correlates with early transcriptomic responses in blood | Npj Vaccines | 2020 | 101 |
| 28 | Access to and equitable distribution of COVID-19 vaccine in low-income countries | Npj Vaccines | 2021 | 101 |
| 29 | Extended interval BNT162b2 vaccination enhances peak antibody generation | Npj Vaccines | 2022 | 101 |
| 30 | COVID-19 vaccines: breaking record times to first-in-human trials | Npj Vaccines | 2020 | 92 |
| 31 | Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology | Npj Vaccines | 2019 | 91 |
| 32 | Neutrophil swarming and extracellular trap formation play a significant role in Alum adjuvant activity | Npj Vaccines | 2017 | 90 |
| 33 | Cell culture-derived influenza vaccines in the severe 2017–2018 epidemic season: a step towards improved influenza vaccine effectiveness | Npj Vaccines | 2018 | 90 |
| 34 | Escherichia coli-derived virus-like particles in vaccine development | Npj Vaccines | 2017 | 88 |
| 35 | Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model | Npj Vaccines | 2017 | 81 |
| 36 | Recent advances in the production of recombinant glycoconjugate vaccines | Npj Vaccines | 2019 | 79 |
| 37 | Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy | Npj Vaccines | 2017 | 78 |
| 38 | Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation | Npj Vaccines | 2021 | 78 |
| 39 | Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation | Npj Vaccines | 2018 | 76 |
| 40 | Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development | Npj Vaccines | 2018 | 75 |
| 41 | The use of viral vectors in vaccine development | Npj Vaccines | 2022 | 73 |
| 42 | Identification of antigens presented by MHC for vaccines against tuberculosis | Npj Vaccines | 2020 | 69 |
| 43 | Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium | Npj Vaccines | 2017 | 68 |
| 44 | Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel | Npj Vaccines | 2022 | 68 |
| 45 | Vaccines for human fungal diseases: close but still a long way to go | Npj Vaccines | 2021 | 67 |
| 46 | Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models | Npj Vaccines | 2021 | 66 |
| 47 | Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees | Npj Vaccines | 2021 | 66 |
| 48 | A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice | Npj Vaccines | 2016 | 65 |
| 49 | Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization | Npj Vaccines | 2020 | 65 |
| 50 | Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy | Npj Vaccines | 2022 | 64 |
